Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Osteogenesis imperfecta.

P H Byers1, R D Steiner

  • 1Department of Pathology, University of Washington, Seattle 98195.

Annual Review of Medicine
|January 1, 1992
PubMed
Summary
This summary is machine-generated.

Osteogenesis imperfecta, or brittle bone disease, is primarily caused by mutations in type I collagen genes. Understanding these genetic causes improves diagnosis and counseling, but new therapies are urgently needed.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cesarean delivery is not associated with decreased at-birth fracture rates in osteogenesis imperfecta.

Genetics in medicine : official journal of the American College of Medical Genetics·2015
Same author

A cross-sectional multicenter study of osteogenesis imperfecta in North America - results from the linked clinical research centers.

Clinical genetics·2014
Same author

Research challenges in central nervous system manifestations of inborn errors of metabolism.

Molecular genetics and metabolism·2010
Same author

Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo-controlled study.

The Journal of clinical endocrinology and metabolism·2010
Same author

Successful endovascular repair of acute type B aortic dissection in undiagnosed Ehlers-Danlos syndrome type IV.

European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery·2009
Same author

Analysis of multigenerational families with thoracic aortic aneurysms and dissections due to TGFBR1 or TGFBR2 mutations.

Journal of medical genetics·2009
Same journal

Dupilumab Emerges as an Effective Antibody Therapy for Eosinophilic Esophagitis.

Annual review of medicine·2026
Same journal

CAR T Cell Toxicities and Emerging Treatment Strategies.

Annual review of medicine·2026
Same journal

Transthyretin Amyloid Cardiomyopathy: A Rapidly Evolving Landscape.

Annual review of medicine·2026
Same journal

Accessibility of Somatic Genetic Testing for Cancer Treatment Decisions.

Annual review of medicine·2026
Same journal

Diffuse Parenchymal Lung Disease: Updates in Pathophysiology and Management.

Annual review of medicine·2026
Same journal

Revascularization for Ischemic Cardiomyopathy: Disproving the 45-Year-Old Concept of Hibernating Myocardium.

Annual review of medicine·2026
See all related articles

Area of Science:

  • Genetics
  • Biochemistry
  • Molecular Biology

Background:

  • Osteogenesis imperfecta (OI), or brittle bone disease, is a group of inherited disorders characterized by fragile bones that break easily.
  • Recent research has significantly advanced the understanding of OI's molecular underpinnings.

Purpose of the Study:

  • To summarize the current understanding of the genetic basis of osteogenesis imperfecta.
  • To highlight the implications of genetic findings for diagnosis and prognosis.
  • To emphasize the need for developing effective medical therapies for OI.

Main Methods:

  • Biochemical analysis of collagen.
  • Linkage studies to identify disease-associated genes.
  • Molecular genetic studies to pinpoint mutations in collagen genes.

Related Experiment Videos

Main Results:

  • Mutations in genes encoding type I collagen chains are the cause of nearly all cases of osteogenesis imperfecta.
  • Genetic studies have greatly enhanced the understanding of the molecular basis of brittle bone disease.
  • These advances have led to improved molecular diagnostic capabilities and prognostic counseling for OI patients.

Conclusions:

  • Genetic mutations in type I collagen are the primary cause of osteogenesis imperfecta.
  • Current understanding facilitates molecular diagnosis and prognostic guidance.
  • Urgent research is required to develop medical therapies to reduce morbidity in osteogenesis imperfecta.